nuclear transport factor 2 pseudogene 6Genealiases: []
Q-omics provides the consensus-scored NUTF2P6 profile across patient tissues and cancer cell-line models. NUTF2P6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NUTF2P6 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, NUTF2P6 RNA expression shows 12,229 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where NUTF2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTF2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTF2P6 survival associations across molecular data types. NUTF2P6 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTF2P6 RNA expression–survival associations across cancer types. High NUTF2P6 expression shows unfavorable associations in KIRC, DLBC, LUAD and MESO, but favorable associations in CHOL and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for NUTF2P6 RNA expression.
This table summarizes NUTF2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NUTF2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTF2P6 shows lower tumor expression in KIRP, BLCA and LUAD and higher tumor expression in STAD, COAD and LIHC. The KIRP box plot shows higher NUTF2P6 RNA expression in normal versus tumor tissue (log2 FC = −0.328, t-test p < 0.001).
This table shows molecular features associated with NUTF2P6 in patient tissues and cancer cell lines. In patient samples, NUTF2P6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
